Rentschler Appoints Stefan Rampf to the Position of CFO

Laupheim, Germany, February 15, 2016 / B3C newswire / -- Rentschler Biotechnologie, a leading contract organization for the development and manufacturing of biopharmaceuticals announces the appointment of Stefan Rampf as new Chief Financial Officer (CFO) effective May 1st, 2016.

Stefan Rampf will be responsible for Commercial Management. The 49-year-old has about one decade's experience as CFO with renowned companies, most recently with ABL Technik Entlackung GmbH, Leutkirch, and, until 2013, with Volvo Financial Services in Frankfurt.

Dr. Nikolaus F. Rentschler: "Stefan Rampf convinces through his excellent expertise and strengthens the Top Management of Rentschler Biotechnologie on its successful way. The Supervisory Board and Management Board are very much looking forward to the cooperation."

Dr. Frank Mathias: "With Stefan Rampf joining Rentschler, the new Management Board will be complete. Together with Thomas Siklosi and the whole Management Team we will continue our close and successful cooperation with our partners and clients and jointly bring the company forward."


Link to the press release


Tweet this press release


About Rentschler Biotechnologie
Rentschler is a full-service Contract Development and Manufacturing Organization (CDMO) and one of the leaders in the industry. With many years of experience the company is a reliable outsourcing partner. Focused on mammalian cell lines, the experience covers the development and manufacturing of biopharmaceuticals for clients, supporting them through to market approval of their products. The high quality of the consulting services and the competent implementation of cGMP and quality management standards ensure the project success. Cutting-edge technologies and cGMP facilities with stainless steel and single-use bioreactors support the flexible and customized cost-efficient manufacturing for clinical studies and market supply. Rentschler is a privately owned company which can act independently on a long-term basis.


Contact

Dr. Marion Schrader
Senior Director Marketing
+49 7392 701-491
[email protected]

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.